Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce C Carleton

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
Paediatric Anaesthesia|October 26, 2016
Oral morphine dosing predictions based on single dose in healthy children undergoing surgeryJoy M Dawes, Erin M Cooke, Jacqueline A Hannam, et al.
Clinical Pharmacology and Therapeutics|February 3, 2018
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateElizabeth J Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Further Investigation of the Role of <i>ACYP2</i> and <i>WFS1</i> Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer PatientsBritt I Drögemöller, Beth Brooks, Carol Critchley, et al.
Pharmacogenomics|August 1, 2015
Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in childrenHenk Visscher, S Rod Rassekh, George S Sandor, et al.
Nature Genetics|November 10, 2009
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapyColin J D Ross, Hagit Katzov-Eckert, Marie-Pierre Dubé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2025
Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin ChemotherapyJoshua Millstein, Shahrad R Rassekh, Austin L Brown, et al.
Canadian Journal of Kidney Health and Disease|March 9, 2017
Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort StudyKelly R McMahon, Shahrad Rod Rassekh, Kirk R Schultz, et al.
Cell Stem Cell|September 15, 2021
RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapyTarek Magdy, Zhengxin Jiang, Mariam Jouni, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 25, 2021
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatmentJennifer J Lin, Catrina M Loucks, Jessica N Trueman, et al.
JAMA Network Open|May 9, 2020
Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for CancerKelly R McMahon, Shahrad Rod Rassekh, Kirk R Schultz, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
Paediatric Anaesthesia|October 26, 2016
Oral morphine dosing predictions based on single dose in healthy children undergoing surgeryJoy M Dawes, Erin M Cooke, Jacqueline A Hannam, et al.
Clinical Pharmacology and Therapeutics|February 3, 2018
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateElizabeth J Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Further Investigation of the Role of <i>ACYP2</i> and <i>WFS1</i> Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer PatientsBritt I Drögemöller, Beth Brooks, Carol Critchley, et al.
Pharmacogenomics|August 1, 2015
Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in childrenHenk Visscher, S Rod Rassekh, George S Sandor, et al.
Nature Genetics|November 10, 2009
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapyColin J D Ross, Hagit Katzov-Eckert, Marie-Pierre Dubé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2025
Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin ChemotherapyJoshua Millstein, Shahrad R Rassekh, Austin L Brown, et al.
Canadian Journal of Kidney Health and Disease|March 9, 2017
Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort StudyKelly R McMahon, Shahrad Rod Rassekh, Kirk R Schultz, et al.
Cell Stem Cell|September 15, 2021
RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapyTarek Magdy, Zhengxin Jiang, Mariam Jouni, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 25, 2021
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatmentJennifer J Lin, Catrina M Loucks, Jessica N Trueman, et al.
JAMA Network Open|May 9, 2020
Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for CancerKelly R McMahon, Shahrad Rod Rassekh, Kirk R Schultz, et al.
Pageof 14